Dicyclomine

證據等級: L5

預測適應症: 2 個

A note before the report: the Evidence Pack itself flags rank 1 (cauda equina syndrome) as a likely spurious/false-positive association (the repurposing_rationale.mechanistic_link explicitly says this). I’m following the prompt’s instruction to build the report around predicted_indications[0], but I’m reporting that caveat transparently rather than presenting it as a strong signal — that’s the honest reading of the data, and inventing confidence that isn’t there would misrepresent the evidence pack.

Dicyclomine: From Irritable Bowel Syndrome (Antispasmodic Use) to Cauda Equina Syndrome

One-Sentence Summary

Dicyclomine is an antimuscarinic (anticholinergic) antispasmodic drug, internationally used for irritable bowel syndrome and functional bowel/spastic colon disorders — it is not currently registered or marketed in South Africa. The TxGNN model’s top-ranked prediction links it to Cauda Equina Syndrome, but this is currently supported by 0 clinical trials and 0 publications, and the model’s own rationale flags the link as a probable indirect artifact rather than a genuine treatment mechanism.

Quick Overview

Item	Content
Original Indication	Not available from SAHPRA data (drug is unregistered in South Africa). Internationally, Dicyclomine is used as an antispasmodic for irritable bowel syndrome / functional bowel disorders.
Predicted New Indication	Cauda Equina Syndrome
TxGNN Prediction Score	99.66%
Evidence Level	L5
South Africa Market Status	Not marketed (未上市)
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack (flagged as a High-severity data gap, DG002). Based on known pharmacological information, Dicyclomine is a non-selective antimuscarinic (anticholinergic) antispasmodic. Its established mechanism is blockade of muscarinic (M1/M3) receptors on gastrointestinal smooth muscle, which relieves spasm in conditions such as irritable bowel syndrome — this is the basis for its original indication.

Cauda equina syndrome, by contrast, is a surgical emergency caused by mechanical compression of the lumbosacral nerve roots, typically from a herniated disc, tumour, or trauma. The standard of care is urgent surgical decompression; there is no established pharmacological treatment for the underlying nerve compression. The Evidence Pack’s own mechanistic rationale is explicit about this mismatch: it states that the only plausible link is indirect — cauda equina syndrome can cause neurogenic bladder as a secondary complication (from sacral nerve root damage), and Dicyclomine’s antimuscarinic effect could theoretically ease secondary bladder symptoms. It does not treat the nerve compression itself, which is the actual disease process.

In other words, this prediction most likely reflects the model learning a “cauda equina syndrome → neurogenic bladder” association path rather than a direct drug–disease treatment relationship. Consistent with this, the Evidence Pack’s second-ranked prediction, neurogenic bladder (obsolete disease term, score 99.50%), has a mechanistically more coherent rationale — antimuscarinic blockade of detrusor M2/M3 receptors is the same mechanism used by approved neurogenic bladder / overactive bladder drugs (e.g. oxybutynin, tolterodine). That prediction is scored by the pack itself as a “Research Question” rather than a candidate for clinical evaluation, again due to zero direct trial or literature support and an outdated disease ontology label requiring disambiguation.

No clinical trials or publications exist for either predicted indication, so this section should be read as a hypothesis-generation signal only, not as clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Dicyclomine (DB00804) has no SAHPRA registrations and is not marketed in South Africa (0 licenses on file). No product, dosage form, or approved indication text is available to report.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: TFDA/SAHPRA label warnings and contraindications are a Blocking data gap (DG001) in this Evidence Pack — no safety review can be completed until this is resolved.)

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence level is L5 (model prediction only — zero clinical trials, zero publications for the top-ranked indication).
The Evidence Pack’s own mechanistic analysis suggests the top prediction (cauda equina syndrome) is likely an indirect/false-positive association rather than a genuine drug–disease treatment relationship, since the drug has no mechanism addressing the underlying nerve compression.
Dicyclomine is not registered or marketed in South Africa, so there is no existing regulatory or safety base to build on locally.

To proceed, the following is needed:

SAHPRA/TFDA-approved Professional Information (label warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action data from DrugBank or primary literature — currently a High-severity data gap (DG002)
Disambiguation of the “obsolete neurogenic bladder (disease)” ontology term to its current equivalent, to properly evaluate the more mechanistically plausible rank-2 prediction
Preclinical or mechanistic studies specifically testing antimuscarinic therapy for neurogenic bladder secondary to cauda equina syndrome, before this moves beyond a research hypothesis
Regulatory pathway assessment, since the drug currently has no South African market presence at all
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.